Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mar 4, 2021
Immunoglobulin Replacement Therapy Cost-Effectiveness Study
Common variable immunodeficiency disorders (CVID), the most common form of primary antibody deficiency, are rare conditions associated with considerable morbidity and mortality.
All
Publication
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247941
Mar 4, 2021
Immunoglobulin Replacement Therapy Cost-Effectiveness Study
Common variable immunodeficiency disorders (CVID), the most common form of primary antibody deficiency, are rare conditions associated with considerable morbidity and mortality.
All
Publication
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247941
Mar 1, 2021
The Source Spring 2021
Magazine of the plasma protein therapeutics industry - Spring 2021
All
The Source Magazine
https://drive.google.com/file/d/1yqFqdfQu0EonQT7d-uQqXcVJfZ9ykOk9/view?usp=sharing
Mar 1, 2021
The Source Spring 2021
Magazine of the plasma protein therapeutics industry - Spring 2021
All
The Source Magazine
https://drive.google.com/file/d/1yqFqdfQu0EonQT7d-uQqXcVJfZ9ykOk9/view?usp=sharing
Feb 25, 2021
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients
February 25, 2021 (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency.
All
Press releases
Feb 25, 2021
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients
February 25, 2021 (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency.
All
Press releases
Feb 10, 2021
Human Plasma Donations Remain Important During COVID-19 Pandemic
In a recent communication, the U.S. Food and Drug Administration (FDA) limits the collection and use of COVID-19 convalescent plasma authorized under Emergency Use Authorization for the treatment of hospitalized patients with COVID-19.1 It is important to note, however, that this development does not mean that the need for plasma donations has diminished.
All
PPTA statements
Feb 10, 2021
Human Plasma Donations Remain Important During COVID-19 Pandemic
In a recent communication, the U.S. Food and Drug Administration (FDA) limits the collection and use of COVID-19 convalescent plasma authorized under Emergency Use Authorization for the treatment of hospitalized patients with COVID-19.1 It is important to note, however, that this development does not mean that the need for plasma donations has diminished.
All
PPTA statements
No results found